^
Association details:
| Biomarker: | VTCN1 expression + DDR |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | puxitatug samrotecan (AZD8205) (Topoisomerase I inhibitor, B7-H4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 1765: Discovery and first disclosure of AZD8205, a B7-H4-targeted antibody-drug conjugate utilizing a novel topoisomerase I linker-warhead
Published date:
06/15/2022
Excerpt:
To understand the biology underlying antitumor response, we conducted a multiparametric analysis including genomics, proteomics and computational pathology and found that deeper antitumor activity was observed in models with elevated B7-H4 expression as well as in models with defects in DNA damage repair (DDR)...These data suggest that AZD8205 is a promising therapeutic candidate for the treatment of B7-H4 positive solid tumors.
DOI:
https://doi.org/10.1158/1538-7445.AM2022-1765
